Correlation Between Lixte Biotechnology and Allarity Therapeutics

Can any of the company-specific risk be diversified away by investing in both Lixte Biotechnology and Allarity Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lixte Biotechnology and Allarity Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lixte Biotechnology Holdings and Allarity Therapeutics, you can compare the effects of market volatilities on Lixte Biotechnology and Allarity Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lixte Biotechnology with a short position of Allarity Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lixte Biotechnology and Allarity Therapeutics.

Diversification Opportunities for Lixte Biotechnology and Allarity Therapeutics

0.19

Correlation Coefficient

Lixte Biotechnology  Allarity Therapeutics

Average diversification

The 3 months correlation between Lixte and Allarity is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Lixte Biotechnology Holdings and Allarity Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allarity Therapeutics and Lixte Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lixte Biotechnology Holdings are associated (or correlated) with Allarity Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allarity Therapeutics has no effect on the direction of Lixte Biotechnology i.e., Lixte Biotechnology and Allarity Therapeutics go up and down completely randomly.

Pair Corralation between Lixte Biotechnology and Allarity Therapeutics

Given the investment horizon of 90 days Lixte Biotechnology Holdings is expected to generate 1.3 times more return on investment than Allarity Therapeutics. However, Lixte Biotechnology is 1.3 times more volatile than Allarity Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Allarity Therapeutics is currently generating about -0.29 per unit of risk. If you would invest  183.00  in Lixte Biotechnology Holdings on September 3, 2024 and sell it today you would earn a total of  40.00  from holding Lixte Biotechnology Holdings or generate 21.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Lixte Biotechnology Holdings  vs.  Allarity Therapeutics

Lixte Biotechnology

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lixte Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point.

Allarity Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Lixte Biotechnology and Allarity Therapeutics

The main advantage of trading using opposite Lixte Biotechnology and Allarity Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lixte Biotechnology position performs unexpectedly, Allarity Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will offset losses from the drop in Allarity Therapeutics' long position.

The idea behind Lixte Biotechnology Holdings and Allarity Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.